Dow Chemical buys stake in Phoenix biotech firm
The Dow Chemical Co. has taken a minority stake in a Phoenix company working to commercialize palm-size breath analyzers with applications in weight and diabetes management, bizjournals.com repots. Kemeta LLC said it acquired the base technology developed by Dow from RoseStreet Labs LLC in April. Since then, Kemeta has been working with physicians and clinics in the field of diabetes and weight management. Kemeta''s palm-size breath sensor provides the user with immediate feedback on their rate of fat metabolism and thus the performance of their daily diet and/or fitness regimen. Kemeta said it plans to introduce the product in 2008. Terms of the deal were not disclosed.